Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany
- Glitazone pretreatment boosted 1-131 uptake. Foster, Melissa // Endocrine Today;Dec2011, Vol. 9 Issue 12, p24
The article reports on a study which found that a short course of treatment with glitazone before radioiodine ablation enhances the uptake of radioactive iodine by cancer cells which could improve the treatment of metastatic differentiated thyroid cancer.
- Reply. Sabri, O. // European Journal of Nuclear Medicine;2001, Vol. 28 Issue 3, p394
Replies to a comment made on an article about the treatment of differentiated nonmedullary thyroid carcinoma. Effect of thyroid uptake of a second application of radioiodine; Results of a reduction in thyroid uptake; Difficulty in quantifying how much of the administered radioiodine is absorbed...
- Evidence supports optional use of RAI for papillary thyroid cancer. Calabro, Anthony; Costa, Samantha; Foster, Melissa // Endocrine Today;Oct2012, Vol. 10 Issue 10, p16
The article reports that Iain J. Nixon, MBCHB, clinical fellow in the head and neck surgery department of Memorial Sloan-Kettering Cancer Center, has argued for the optional use of radioactive iodine for the management of papillary thyroid cancer.
- Post-therapy whole-body scan with abnormal radioactive iodine localized to the head of two women. Lee, Stephanie L. // Endocrine Today;Jan2011, Vol. 9 Issue 1, p19
This article discusses the case of a young woman who received radioactive iodine remnant ablation for multifocal micropapillary thyroid carcinoma.
- Historical Note: TSH Suppression for Thyroid Cancer. Hurley, James R. // Thyroid;Nov2011, Vol. 21 Issue 11, p1175
The article discusses the suppression of thyroid-stimulating hormone (TSH) for thyroid cancer treatment. The author notes the rapid advances in thyroid disease diagnosis and treatment due to radioiodine availability in the 1940s. He presents some findings on TSH suppression as well as the...
- Treatment of differentiated thyroid cancers. T�r�ner, F�sun Balos // Turkish Journal of Cancer;Oct2005, Vol. 35 Issue 4, p153
Although several guidelines have been published for the management of differentiated thyroid cancers, there are still some controversies. Besides an effective initial therapy, long term follow-up of the patients with differentiated thyroid cancers is important for the optimum management and this...
- Controversies and challenges in the management of well-differentiated thyroid cancer. Iyer, N.; Shaha, Ashok // Indian Journal of Surgery;Dec2009, Vol. 71 Issue 6, p299
The incidence of well-differentiated thyroid cancer has seen a worldwide increase in the last three decades, although whether this is due to a �true increase� in incidence or simply increased detection of otherwise subclinical disease remains undetermined. Nonetheless, this rising incidence...
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. Mallick, Ujjal; Harmer, Clive; Yap, Beng; Wadsley, Jonathan; Clarke, Susan; Moss, Laura; Nicol, Alice; Clark, Penelope M.; Farnell, Kate; McCready, Ralph; Smellie, James; Franklyn, Jayne A.; John, Rhys; Nutting, Christopher M.; Newbold, Kate; Lemon, Catherine; Gerrard, Georgina; Abdel-Hamid, Abdel; Hardman, John; Macias, Elena // New England Journal of Medicine;5/3/2012, Vol. 366 Issue 18, p1674
Background: It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid cancer or whether the effects of radioiodine (especially at a low dose) are influenced by using either...
- Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Jarzab, Barbara; Handkiewicz-Junak, Daria; Roskosz, J�zef; Puch, Zbigniew; Wygoda, Zbigniew; Kukulska, Aleksandra; Jurecka-Lubieniecka, Beata; Hasse-Lazar, Kornelia; Turska, Maria; Zajusz, Aleksander // European Journal of Nuclear Medicine & Molecular Imaging;2003, Vol. 30 Issue 8, p1077
We sought to evaluate the efficacy, biochemical effects, safety and outcome of recombinant human thyroid-stimulating hormone (rhTSH) as an adjunct to radioiodine treatment of advanced differentiated thyroid carcinoma (DTC). We also sought to determine whether rhTSH is useful as an adjunct to...